Senzime ABSNZZF 68 Net Margin % is -96.87% as of Mar. 2026. GuruFocus rates SNZZF with a GF Score™ of 68/100 and a GF Value™ of $1.21 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Senzime AB ranks worse than 83.23% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Senzime AB's Net Income for the
three
months ended in Mar. 2026 was $-2.42 Mil. Senzime AB's Revenue for the
three
months ended in Mar. 2026 was $2.49 Mil. Therefore, Senzime AB's net margin for the quarter that ended in Mar. 2026 was -96.87%.
The historical rank and industry rank for Senzime AB's Net Margin % or its related term are showing as below:
SNZZF'
s Net Margin % Range Over the Past 10 Years
Min: -6892.59 Med: -543.13 Max: -120.74
Current: -120.74
SNZZF's Net Margin % is ranked worse than 83.23% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs SNZZF: -120.74
Senzime AB (OTCPK:SNZZF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Senzime AB Net Margin % Related Terms
Senzime AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Senzime AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Senzime AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Senzime AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senzime AB (SNZZF) has a Net Margin % of -96.87% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Senzime AB and its competitors. According to the industry distribution chart, Senzime AB ranks #680 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 83.2%.
Is Senzime AB's Net Margin % too high?
Senzime AB's current Net Margin % is -96.87%. Based on the distribution chart, Senzime AB ranks #680 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Senzime AB has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #680 out of 817 companies for Net Margin %. This places Senzime AB in the lower half of its industry. The industry median Net Margin % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Senzime AB and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senzime AB's current Net Margin % is -96.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Based on GuruFocus' analysis, Senzime AB (SNZZF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.21, compared to a current price of $0.48 — trading 60.5% below its estimated fair value. The current Net Margin % is -96.87%. Senzime AB's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Senzime AB (SNZZF), the current Net Margin % is -96.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (SNZZF) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of $0.48 is trading 60.5% below its estimated GF Value™ of $1.21.
GuruFocus considers Senzime AB to be Possible Value Trap.
Key valuation signals for SNZZF:
Net Margin %: -96.87%
GF Value™: $1.21 vs. price of $0.48 (60.5% below fair value)
No single metric tells the full story. See the SNZZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
68GF Score
Get the complete analysis for SNZZF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNZZF has been successfully added to your 
